Amgen Restructures Due to Lower Aranesp® Revenues While Continuing to Invest in Innovation and Future Growth

Amgen Restructures Due to Lower Aranesp® Revenues While Continuing to Invest in Innovation and Future Growth

Expects to Reduce Staff by 12-14 Percent

Pre-Tax Restructuring Charges of $600 Million – $700 Million Anticipated

Changes Adjusted Earnings Guidance for 2007 from $4.28 to a Range of $4.13 – $4.23 Per Share

Amgen (NASDAQ: AMGN) today announced initiatives that will reduce company staff by 12-14 percent and deliver other operational efficiencies while ensuring continued investment at industry-leading levels in research and development. These initiatives will be substantially completed by 2008 and yield pre-tax savings from prior plan of between $1.0 billion – $1.3 billion in 2008. Cumulative pre-tax restructuring charges associated with these changes are expected to be $600 million – $700 million in 2007 and 2008, which includes $289 million for asset impairment and related costs reported in the second quarter. The company also announced that adjusted earnings per share guidance for 2007 has been changed from $4.28 to a range of $4.13 – $4.23, excluding restructuring charges, due to lower Aranesp® revenues. Adjusted earnings per share (EPS) guidance excludes restructuring charges, stock option expense, certain expenses related to acquisitions and certain other items. These expenses and other items are itemized on the reconciliation table below.

“At Amgen we have always been committed to investing in the future while squarely facing the challenges of today,” said Kevin Sharer, Amgen’s chairman and chief executive officer. “Recent changes in coverage rules and adjustments to Amgen’s FDA approved labels for EPOGEN® and Aranesp have and will adversely affect Amgen’s revenue. The initiatives announced today respond to that new reality by taking account of reduced revenues and appropriately lowering costs across the company. We will continue to strongly support our research efforts directed at development of new medicines for grievously ill patients. These changes will also position Amgen for success in 2008 and beyond.”

Plans announced by the company to improve its cost structure include:
Reducing headcount by 12-14 percent, or approximately 2,200-2,600 staff;
Reducing planned capital expenditures by approximately $1.9 billion during the period 2007-2008, with a resulting improvement in cash flow;
Closing certain production operations and rationalizing other facilities to achieve improved efficiencies; and
Making choices about the highest priorities in research and development and operations that build the framework for future growth.

These initiatives will be implemented in a manner designed to ensure continued responsiveness to the needs of customers and patients, the fair treatment of all staff and the future health of the company. The company plans to minimize the impact of the targeted reduction in force on our people through the use of attrition, hiring freezes and a voluntary transition program. Amgen staff adversely affected by these initiatives will be treated with respect and receive career counseling assistance in securing new employment.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.